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Summary
The E2F transcription factors mediate the activation or repression of key cell cycle regulatory genes under the control of
the retinoblastoma protein (pRB) tumor suppressor and its relatives, p107 and p130. Here we investigate how E2F4,
the major “repressive” E2F, contributes to pRB’s tumor-suppressive properties. Remarkably, E2F4 loss suppresses the
development of both pituitary and thyroid tumors in Rb/ mice. Importantly, E2F4 loss also suppresses the inappropriate
gene expression and proliferation of pRB-deficient cells. Biochemical analyses suggest that this tumor suppression occurs
via a novel mechanism: E2F4 loss allows p107 and p130 to regulate the pRB-specific, activator E2Fs. We also detect these
novel E2F complexes in pRB-deficient cells, suggesting that they play a significant role in the regulation of tumorigenesis
in vivo.
Introduction teins, that also includes p107 and p130 (reviewed by Dyson,
1998; Trimarchi and Lees, 2002). p107 and p130 share many
The retinoblastoma protein (pRB) was the first identified tumor properties with pRB: they bind to E2F in vivo, inhibit E2F tran-
suppressor, and it is mutated in approximately one third of all scriptional activity, and recruit HDACs to mediate the active
human tumors. pRB blocks cells in G1 by inhibiting the activity repression of E2F-responsive genes. However, there are dra-
of a cellular transcription factor, E2F, that controls the expres- matic differences in the tumor-suppressive properties of the
sion of key components of the cell cycle and DNA replication individual pocket proteins (reviewed by Mulligan and Jacks,
machinery (reviewed in Dyson, 1998; Trimarchi and Lees, 2002). 1998). Inheritance of a single Rb mutant allele predisposes both
pRB regulates E2F through two distinct mechanisms. First, its mice and humans to tumors with 100% penetrance. The tumors
association is sufficient to block E2F transcriptional activity. consistently lose the wild-type Rb allele, confirming that pRB
Second, the pRB-E2F complex can recruit histone deacetylases
behaves as a classical tumor suppressor. In contrast, the loss
(HDACs) to the promoters of E2F-responsive genes and thereby
of p107 and/or p130 does not appear to promote tumorigenicityactively repress their transcription. Cell cycle entry requires the
in mice or cells (Cobrinik et al., 1996; Lee et al., 1996). Yetphosphorylation of pRB and its subsequent dissociation from
there is growing evidence that mutation of p107 and/or p130E2F. This phosphorylation is mediated by cell cycle-dependent
promotes tumor formation when pRB is also inactivated. Thiskinase complexes, cyclin D-CDK4/6, and cyclin E-CDK2. Impor-
is exemplified by Rb/;p107/ chimeric mice, which de-tantly, tumors that retain wild-type pRB almost always carry
velop an additional tumor type, retinoblastoma, comparedactivating mutations in cyclin D1 or CDK4 or inactivating muta-
to Rb/ chimeras (Robanus-Maandag et al., 1998), andtions in the cdk4 inhibitor, p16 (reviewed by Bartek et al., 1996;
Rb/;p107/;p130/ mouse embryonic fibroblasts (MEFs),Sherr, 1996). This suggests that the functional inactivation of
which are more tumorigenic than Rb/ controls (DannenbergpRB, and the resulting deregulation of E2F, is an essential step
et al., 2000; Sage et al., 2000). Biochemical and mechanisticin tumorigenesis.
pRB belongs to a family of proteins, called the pocket pro- studies in cells deficient for different pocket protein family mem-
S I G N I F I C A N C E
Understanding how the E2F and pRB family members contribute to the regulation of tumorigenesis is a key goal. Our finding of tumor
suppression in the Rb/;E2f4/ mice through the formation of novel E2F complexes in Rb/;E2f4/, Rb/;E2f4/, and Rb/ cells
strongly suggests that tumor formation is critically and exclusively dependent upon the inactivation of pRB, rather than p107 or p130,
because it triggers the release of the normally pRB-specific, activator E2Fs. However, p107 and p130 assume significant tumor-
suppressive properties in pRB-deficient cells because they can substitute for pRB in the regulation of these activator E2Fs. This model
suggests a novel strategy for the generation of chemotherapeutics that would act by increasing the available pools of p107 and
p130.
CANCER CELL : DECEMBER 2002 · VOL. 2 · COPYRIGHT  2002 CELL PRESS 463
A R T I C L E
bers should help to identify the critical, tumor suppressive func- for the repressive pRB-E2F complexes in tumor suppression.
Indeed, numerous overexpression studies have led to the con-tion(s) of pRB.
To date, eight genes have been identified as components clusion that regulation of E2F-responsive genes, and therefore
cell cycle entry, is largely controlled by the repressive, and notof the E2F transcriptional activity (reviewed by Dyson, 1998;
Helin, 1998). These genes have been divided into two distinct activating, E2Fs (Dahiya et al., 2001; Zhang et al., 1999, 2000).
In this study, we use Rb;E2f4 compound mutant mice to investi-groups: the E2fs (E2f1 through E2f6) and the DPs (DP1 and DP2).
The protein products from these two groups heterodimerize to gate whether repressive E2F complexes contribute to tumor
suppression. This analysis shows that the absence of E2F4give rise to functional E2F activity (Bandara et al., 1993; Helin
et al., 1993; Krek et al., 1993). The functional specificity of the suppresses the formation of pRB-deficient tumors by promoting
the formation of novel complexes between the activating E2FsE2F-DP complex is primarily determined by the identity of the
E2F subunit. The pocket protein binding E2Fs can be divided and p107 and p130 as well as correcting inappropriate target
gene expression and cell growth. Most significantly, these datainto two subgroups that appear to have opposing roles in vivo
(reviewed by Trimarchi and Lees, 2002). provide support for a model in which pocket proteins function
as tumor suppressors by controlling activator E2Fs rather thanThe first E2F subgroup includes E2F1, 2, and 3. These E2Fs
play a key role in promoting the activation of E2F-responsive by forming repressive E2F complexes.
genes, and thereby cell cycle entry. Chromatin immunoprecipi-
tation (ChIP) experiments confirm that these E2Fs associate Results
with the promoters of known target genes coincident with their
activation in late G1 (Rayman et al., 2002; Takahashi et al., 2000). Loss of E2F4 extends lifespan and alters tumorigenesis
in Rb mutant miceMEFs lacking E2F3 or E2F1, E2F2, and E2F3 exhibit reduced
E2F target gene expression and significant proliferative defects Overexpression studies strongly suggest that the repressive
E2F-pocket protein complexes play a critical role in controlling(Humbert et al., 2000b; Wu et al., 2001). Furthermore, the ec-
topic expression of E2F1, 2, or 3 is sufficient to induce quiescent the expression of E2F-responsive genes. Given this finding,
we wished to establish whether these repressive E2F-pocketcells to initiate E2F-responsive gene expression and cell cycle
re-entry (DeGregori et al., 1997; Lukas et al., 1996). Importantly, protein complexes contribute to tumor suppression. E2F4 is the
major repressive E2F in vivo, accounting for the majority of thethese so-called “activator” E2Fs are specifically regulated by
pRB but not by p107 or p130 in vivo (Moberg et al., 1996). endogenous pRB-, p107- and p130-associated E2F activity.
Thus, if the repressive E2F complexes are important, E2F4 lossE2F4 and E2F5 represent the second E2F subgroup. The
transcriptional properties of these E2Fs are largely determined should exacerbate the formation of pRB-deficient tumors. To
test this hypothesis, we intercrossed Rb and E2f4 mutant mouseby their subcellular localization (Gaubatz et al., 2001; Magae et
al., 1996; Muller et al., 1997; Verona et al., 1997). The endoge- strains with the same C57BL/6 X 129/Sv mixed background.
We then compared the lifespan and tumor phenotype of Rb/,nous E2F4-DP and E2F5-DP complexes are localized in the
cytoplasm and are therefore unable to contribute to the activa- Rb/;E2f4/ and Rb/;E2f4/ littermates.
The phenotype of the Rb/ mice was entirely consistenttion of E2F-responsive genes. However, pocket protein binding
enables the nuclear localization of E2F4 and E2F5. As a result, with previous studies (reviewed by Mulligan and Jacks, 1998).
All mice died between 8.5 and 13.9 months of age (Figure 1A).E2F4 and E2F5 appear to be primarily involved in the active
repression of E2F-responsive genes. E2F4 associates with pRB, Histological examination confirmed that the cause of death was
intermediate lobe pituitary tumors and that the vast majority ofp107, and p130 in vivo and accounts for the majority of the
repressive pocket protein complexes (Moberg et al., 1996). E2F5 the Rb/ animals (23/27) also displayed c-cell thyroid tumors
(Figures 1A and 1B; data not shown). Mutation of a single E2f4is expressed in G0 cells and is primarily regulated by p130
(Hijmans et al., 1995; Sardet et al., 1995). ChIP assays confirm allele did not significantly alter the lifespan of Rb/ animals
(Figure 1A). Moreover, the Rb/;E2f4/ mice developed pitu-that E2F4, p107, p130, and HDAC specifically associate with
E2F-responsive promoters in G0/G1 cells under physiological itary (55/57) and thyroid (47/57) tumors that were comparable
to those arising in the Rb/ controls with respect to both inci-conditions (Rayman et al., 2002; Takahashi et al., 2000). Impor-
tantly, MEFs deficient for E2F4 and E2F5 are unable to arrest dence and size (Figure 1B; data not shown). Thus, a reduction
in the levels of E2F4 had no notable effect on tumorigenicity inin G1 in response to a variety of growth arrest signals, suggesting
that the repressive E2Fs promote cell cycle arrest (Gaubatz et the Rb mutant mice.
Remarkably, the phenotype of Rb/;E2f4/ animals di-al., 2000).
Considerable attention has focused on understanding how verged considerably from those of their littermate controls. First,
there was a significant difference (p  0.0033) in lifespan of thethe growth-suppressive properties of pRB relate to its role in
the inhibition of the activating E2Fs versus its participation in Rb/;E2f4/ versus the Rb/ animals (Figure 1A; Table 1). Two
of the Rb/;E2f4/ mice died at early ages (2.7 and 5.4 months)repressive pRB-E2F complexes. The analysis of Rb;E2f1 and
Rb;E2f3 compound mutant mice has shown that the absence as a result of an increased susceptibility to infections. This is a
characteristic phenotype of the E2f4/ mice and was thereforeof E2F1 or E2F3 is sufficient to suppress both the ectopic S
phase entry and p53-dependent apoptosis arising in pRB-defi- an anticipated outcome for a fraction of the Rb/;E2f4/ mice.
However, we unexpectedly found that neither of these animalscient embryos (Tsai et al., 1998; Ziebold et al., 2001). Moreover,
E2F1 deficiency significantly diminishes the development of tu- had any evidence of tumorigenic lesions (data not shown), even
though such lesions are routinely observed in the pituitaries ofmors in Rb/ mice (Yamasaki et al., 1998). These data suggest
that the inappropriate release of the activator E2Fs makes a Rb/ mice by 3 months of age (Nikitin and Lee, 1996). Most
importantly, the majority of the Rb/;E2f4/ mice (17/19) sur-significant contribution to the phenotypic consequences of pRB
deficiency. However, these experiments do not rule out a role vived at least until the window of lethality of the Rb/ littermate
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Rb/;E2f4/ mice displayed any evidence of pituitary tumors,
although they were detected in some of the older Rb/;E2f4/
mice (Table 1). However, the incidence of pituitary tumors was
significantly lower than in the Rb/ controls (p  0.000092),
and there was a considerable range in size in the tumors that
did arise in the Rb/;E2f4/ animals (Table 1; Figure 1B; data
not shown). Three of the older Rb/;E2f4/ animals (16.2, 20.5,
and 23 months) eventually developed tumors comparable to
those seen in the Rb/ mice (8.5–13.9 months), but others
developed very early lesions or mid-sized tumors (16.5 and 26.6
months), and two animals had completely normal pituitaries
(18.2 and 18.5 months).
E2F4 loss had an even greater effect on the development
of thyroid tumors in Rb/ mice (p  0.00000034). Despite the
extremely high incidence of c-cell thyroid tumors in the Rb/
(23/27) and Rb/;E2f4/ (47/57) animals, only 1/17 of the
Rb/;E2f4/ mice developed a thyroid tumor (Table 1; data not
shown). Indeed, there was no evidence of thyroid hyperplasia in
the remaining 16/17 Rb/;E2f4/ animals. Thus, we conclude
that the absence of E2F4 dramatically suppresses the develop-
ment of both pituitary and thyroid tumors in the Rb/ mice and
thereby greatly extends their lifespan.
Loss of E2F4 induces profound rearrangement
of E2F-pocket protein complexes
We initiated the tumor studies with the expectation that E2F4
loss would either have no effect on or would exacerbate the
formation of pRB-deficient tumors depending on whether or not
the repressive E2F-pocket protein complexes were important
for tumor suppression. Instead, our data clearly show that E2F4
loss inhibits the formation of tumors. To establish the underlying
mechanism, we characterized the effect that E2F4 loss had
on the remaining E2F-pocket protein complexes. Initially, we
compared the E2F complexes present in extracts from wild-
type, Rb/, and Rb/;E2f4/ MEFs by immunoprecipitating
specific E2Fs and then Western blotting to identify the associ-
Figure 1. Loss of E2F4 extends the lifespan of Rb/ adults by reducing the
ated pocket proteins. Consistent with previous studies, E2F1tumor incidence
and E2F3 bound specifically to pRB in wild-type and Rb/ cellsA: Survival curves for Rb/ (blue, n  27), Rb/;E2f4/ (green, n  61), and
(Figure 2; data not shown). In contrast, in Rb/;E2f4/ MEFs,Rb/;E2f4/ (red, n  15) mice. Rb/;E2f4/ mice with no evidence of
tumor formation (open circles) and those with tumors (closed circles) are activating E2Fs participated in novel pocket protein complexes
shown, but the animals that were prematurely sacrificed are not included. in addition to binding to pRB. Specifically, E2F1 bound to p130,
B: Representative H&E stained median sections of adult heads including and E2F3 associated with p107. This was not due to an alteration
the pituitary (marked with an arrow) from (i) control Rb/;E2f4/ animal,
of E2F1 or E2F3 levels since steady-state amounts of these(ii) Rb/;E2f4/, (iii) Rb/;E2f4/, and (iv–vi) Rb/;E2f4/ mice. The older
proteins were not affected in cells deficient for either pRB orRb/;E2f4/ mice have a variety of pituitary phenotypes including (iv) small,
early pituitary tumors, (v) normal pituitaries, and (vi) medium intermediate pRB and E2F4 relative to wild-type MEFs (see Supplemental
lobe pituitary tumors. Magnification, 20. Figure S1C at http://www.cancercell.org/cgi/content/full/2/6/
463/DC1; data not shown). Thus, E2F4 loss allows p107 and
p130 to substitute for pRB by binding E2F1 and E2F3.
Since the activating E2Fs are known to be important down-
controls (8.5–13.9 months). Moreover, 4 months after the death stream targets of the pRB tumor suppressor, the formation of
of the oldest surviving Rb/ animal, half of the Rb/;E2f4/ novel complexes between activating E2Fs and p107 and p130
mice remained alive and healthy. Indeed, a significant fraction could account for the suppression of tumors in the Rb/;E2f4/
of the Rb/;E2f4/ animals lived to an age (20–27 months) mice. To address this issue, we used electrophoretic mobility
comparable to wild-type controls (Figure 1A; Table 1). Thus, the shift assays to establish whether these novel complexes were
absence of E2F4 actually extended the lifespan of the Rb/ present in Rb/;E2f4/ tissues. For these experiments, we
mice. immunoprecipitated p107 from extracts derived from several
Consistent with the prolonged lifespan, E2F4 loss greatly tissues, including the pituitary, which is prone to tumors in Rb/
suppressed the formation of tumors in the Rb/ mice (Table animals. The associated E2F species were released by the addi-
1). Histological examination showed that the vast majority of tion of the detergent deoxycholate (DOC) and then identified in
the Rb/;E2f4/ animals died as a result of defects typical of electrophoretic mobility shift assays (Figure 3). Regardless of
the tissue examined, p107 associated specifically with E2F4 inthe E2f4/ mice. Indeed, prior to 16 months of age, none of the
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Table 1. Histological analysis of Rb/;E2f4/ mice
Age (months) Pituitary tumor Thyroid tumor Cause of death
2.7 — — Sinusitis
5.4 — — Pylonephritis
8.7 — — Sacrificed early
9.3 — — Unknown
9.4 — — Severe dermatitis
10.7 — — Dermatitis, Aspiration
12.6 — — Severe dermatitis
15.6 — — Sacrificed early
16.2  — Pituitary tumor
16.5   Thyroid tumor and metastasis
18.2 — — Histiocytic sarcoma
18.5 — — Sacrificed early
18.6  — Sacrificed early
20.5  — Pituitary tumor
20.8  — Hemangiosarcoma
23.0  — Pituitary tumor and pheochromocytoma
26.0 ND ND Alive
26.6  — Infection of reproductive organs
27.0 ND ND Alive
ND—not determined.
Tumor size is indicated as follows: “” indicates very early tumor growth and “” indicates tumors comparable to those of Rb/ mice.
the wild-type and Rb/ mutant mice (Figures 3A, 3B, and 3D). 4A). DOC release and electrophoretic mobility shift assays con-
firmed that E2F4 and E2F5 accounted for all of the p107- andIn contrast, p107 bound at least three distinct E2F complexes
p130-associated E2F activity in wild-type cells (Figure 4A). Inin the tissues derived from the Rb/;E2f4/ mice (Figures 3C
agreement with our analysis of Rb/;E2f4/ samples, some ofand 3D). An anti-E2F5 antibody recognized one of these spe-
the p107- and p130-associated E2F species in Rb/;E2f4/cies, and the other E2F complexes were completely retarded
MEFs were unaffected by anti-E2F4 and anti-E2F5 antibodies.by a combination of antibodies against E2F1 and E2F3. E2F1
The remaining complexes corresponded to E2F1, E2F3a, andand E2F5 were also observed when the immunoprecipitations
E2F3b (data not shown). Importantly, we found that the spec-were conducted with anti-p130 antibodies (data not shown).
trum of E2F complexes in the Rb/ MEFs was a composite ofThus, the absence of E2F4 enables p107 and p130 to bind
those of the wild-type and Rb/;E2f4/ MEFs. Specifically,activator E2Fs in a variety of tissues, including the tumor-prone
whereas E2F4 accounted for either all or a large fraction ofpituitary.
the p107-associated E2F activity in wild-type and Rb/ cells,It is well documented that the formation of tumors in Rb/
respectively, p107 bound significant quantities of activator E2Fsmice is dependent upon the inactivation of the wild-type Rb
in Rb/ and Rb/;E2f4/ MEFs. Further, p130 associated al-allele. Therefore, we also determined the nature of the E2F
most exclusively with E2F4 in Rb/ cells, but in the doubly
complexes in Rb/ versus Rb/;E2f4/ cells. Since the Rb/ deficient cells, it associated to a large extent with E2F1 and
and Rb/;E2f4/ animals both die in utero (reviewed by Mulli- E2F5 (Figure 4A and see below).
gan and Jacks, 1998; E.Y.L. and J.A.L., unpublished observa- This analysis raised the possibility that p107 and p130 might
tions), these experiments were conducted using MEFs (Figure act in pRB-deficient cells to bind to E2F1 and E2F3 even in the
presence of physiological levels of E2F4. To further test this
hypothesis, we examined the pocket protein binding properties
of E2F1 and E2F3 in Rb/ and Rb/;E2f4/ MEFs by immuno-
precipitating the activator E2Fs and Western blotting for associ-
ated pocket proteins (Figure 4B). These experiments confirmed
that there was a robust association between the activating E2Fs
and p107 and p130 in Rb/ cells. Furthermore, the absence
of both E2F4 and pRB strikingly increased the level of E2F1-
associated p130 when compared to Rb/ cells. Taken together,
these data yield two important conclusions. First, in pRB-defi-
cient cells, p107 and p130 appear to substitute for pRB in the
regulation of the activating E2Fs. Second, E2F4 loss enhances
the formation of these novel complexes, presumably by increas-
ing the levels of the free pools of p107 and p130.
Loss of E2F4 suppresses inappropriate E2F target
gene expression and cell proliferationFigure 2. E2F complex rearrangement in Rb/; E2f4/ MEFs
in pRB-deficient cellsWestern blot detection of pRB, p107, and p130 after immunoprecipitation
Our experiments indicated that tumor suppression in animalsof lysates from wild-type and Rb/; E2f4/ MEFs with anti-E2F1 and anti-
E2F3 antibodies. Input lysate (10% of total) is shown at right. lacking both pRB and E2F4 resulted from the reassortment
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Figure 3. p107 associates exclusively with E2F4 in
organs of wild-type and Rb/ mice but associ-
ates with E2F1, 3, and 5 in Rb/;E2f4/ mice
A–C: Immunoprecipitation, DOC release, and
EMSA were performed with anti-p107 antibody,
using homogenates of adrenal glands (A and C,
500g; B, 300g), liver (A–C, 2 mg), lymph nodes
(L.N.) (A and C, 500 g; B, 250 g), and spleen
(A and C, 200 g; B, 100 g) of wild-type, Rb/,
and Rb/;E2f4/ mice.
D: Coupled immunoprecipitation-DOC release
of E2F proteins in pituitary homogenates of wild-
type (130 g) and Rb/;E2f4/ (200 g) mice
with anti-p107 antibody. Specific E2F-DNA com-
plexes in the absence of antibody retardation
are indicated. The identities of each of the dis-
tinct p107/E2F complexes in Rb/;E2f4/ tissues
were deduced by performing EMSA assays on
MEFs deficient for individual E2F family members
as well as compound E2F mutant cells.
of complexes such that p107/p130 associated with activating pression of known E2F-responsive genes, cyclin E and p107
(Herrera et al., 1996; Hurford et al., 1997). Given the apparentE2Fs. Given these findings, we investigated whether loss of
E2F4 had an impact on the proliferative capacity of Rb-deficient rescue of the Rb/ proliferation defect in Rb/;E2f4/ MEFs,
we hypothesized that the loss of E2F4 might also modulateMEFs. To address this issue, we compared the levels of prolifer-
ation in wild-type, Rb/, and Rb/;E2f4/ MEFs grown to con- the expression of E2F-responsive genes. We investigated this
possibility by examining expression of the cyclin E gene in wild-fluence. Wild-type cells incorporated BrdU at low levels, as
expected for a quiescent population (Figures 5A and 5B). In type, Rb/, and Rb/;E2f4/ MEFs grown to confluence. As
expected from previous studies (Herrera et al., 1996; Hurfordcontrast, Rb/ cells largely failed to arrest in response to con-
fluent growth, and approximately 40% of the cells entered S et al., 1997), cyclin E was expressed at very low levels in conflu-
ent, wild-type cells but was markedly elevated in cells deficientphase. Remarkably, loss of E2f4 completely suppressed this
inappropriate proliferation and restored the low levels of BrdU for Rb (Figure 5C). In striking contrast, cyclin E RNA levels were
dramatically and consistently reduced in cells deficient for bothincorporation observed in wild-type cells.
The abnormal proliferation observed in confluent Rb/ Rb and E2f4 to levels that approximated those observed in wild-
type cells. We demonstrated that each of these effects wasMEFs has been shown to correlate with the inappropriate ex-
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Figure 4. E2F complex rearrangement in Rb/
MEFs and enhanced by further loss of E2F4
A–B: MEFs were lysed with ELB buffer and were
subjected to immunoprecipitation, DOC re-
lease, and EMSA with p107 or p130 antibodies
(A) or were immunoprecipitated with anti-E2F1
or anti-E2F3 antibodies and Western blotted with
pocket protein antibodies (B). Specific E2F-DNA
complexes in the absence of antibody retarda-
tion are indicated.
specific, since expression of a second E2F target gene, B-myb, pressive properties of pRB. Since E2F4 cooperates with the pocket
known to be under the control of p107/p130 but not pRB (Hur- proteins in gene repression, we anticipated that E2F4 loss would
ford et al., 1997; Rayman et al., 2002), was not affected by either exacerbate or have no effect on the tumor phenotype of
mutation of Rb or Rb and E2f4 (Figure 5C; data not shown). the Rb/ mice depending upon whether or not repression was
To extend these findings, we performed Western blotting on important. Instead, we found that the absence of E2F4 greatly
extracts derived from wild-type and mutant MEFs and examined inhibited the formation of both pituitary and thyroid tumors,
expression of several E2F target genes. These experiments con- enabling a significant fraction of the Rb/;E2f4/ mice to live
firmed our RT-PCR studies and showed that expression of cyclin as long as wild-type controls. Indeed, the degree of tumor sup-
E and a second established pRB target, p107, was markedly pression significantly exceeded that resulting from the loss of
elevated in Rb-deficient cells. Furthermore, simultaneous loss the activating E2Fs, E2F1 or E2F3, in an Rb/ background
of E2f4 largely reversed this deregulation in two independent (Yamasaki et al., 1998; U.Z. and J.A.L., unpublished observa-
preparations of doubly null MEFs (Figure 5D). These findings
tions). Furthermore, we demonstrated that loss of E2f4 in Rb-strongly suggest that loss of E2f4 suppresses tumorigenic
deficient cells restored the control of E2F-responsive genesgrowth of Rb-deficient cells by restoring both appropriate levels
and the inhibition of DNA synthesis characteristic of wild-type,of expression of critical E2F target genes and a normal response
confluence-arrested cells. Since the loss of contact inhibitionto cues that limit cell proliferation.
is one of the hallmarks of a cancer cell, we suggest that this
finding could explain the tumor suppression we observe in pitu-Discussion
itaries and thyroids of Rb/;E2f4/ mice. Thus, this study pro-
vides direct evidence for a critical role of E2F4 in pRB function.The goal of these studies was to establish whether the formation
of repressive E2F complexes contributes to the tumor-sup- E2F4 loss could be exerting its tumor-suppressive effects
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Figure 5. Loss of E2F4 restores confluence arrest and regulation of target genes in Rb/ MEFs
A: Immunofluorescence for BrdU (red) and DAPI (blue) on wild-type, Rb/, and Rb/;E2f4/ MEFs treated with BrdU 2 days after reaching confluence.
B: Quantification of BrdU incorporation. For each genotype, the percentage of BrdU-positive nuclei was calculated. The graph depicts the average of
two experiments with standard deviation.
C: RT-PCR analysis of E2F target genes, cyclin E and B-myb (not deregulated in Rb/ MEFs), and actin (loading control) on day 2 confluent cells. Wild-type
3T3 cells were used as a positive control.
D: Western blot analysis of E2F target genes, cyclin E and p107, and -tubulin (loading control) on day 2 confluent cells. Asynchronously growing
p107/;p130/ MEFs were used as a negative control for the p107 blot.
via several possible mechanisms. The simplest model is that specifically occupies E2F-responsive promoters in association
with p107 and p130 during the G0/G1 stages of the cell cycleE2F4 contributes to the activation of E2F-responsive genes and
is therefore a key downstream target of pRB in a similar manner when these targets are transcriptionally repressed (Rayman et
al., 2002; Takahashi et al., 2000). Finally, primary cells that areto E2F1 and E2F3. This conclusion is supported by early studies
that showed that E2F4 has significant transcriptional activity in deficient for E2F4 and E2F5 are defective in cell cycle arrest
but not proliferative functions (Gaubatz et al., 2000). Clearly,overexpression experiments (Beijersbergen et al., 1994; Gins-
berg et al., 1994). However, analysis of the endogenous E2F4 these data do not rule out the possibility that E2F4 could contrib-
ute to the activation of E2F-responsive genes in pRB-deficientprotein does not support this conclusion. First, the predominant
cytoplasmic localization of the free E2F4-DP complexes is in- tumor cells, and experiments that investigate both expression
profiles and promoter occupancy of target genes will be neededconsistent with their role in transcriptional activation (Gaubatz
et al., 2001; Magae et al., 1996; Muller et al., 1997; Verona et to address this issue further. Moreover, it is important to note
that although it is widely assumed that E2F1 and E2F3 contributeal., 1997). Second, ChIP assays strongly suggest that E2F4
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to the formation of tumors through this mechanism, this has
not yet been demonstrated. Therefore, experiments with Rb;E2f
compound mutant cells will be critical in testing this hypothesis
as well.
An alternative model arising from our data suggests that
E2F4 loss could increase the apoptotic potential of pRB-defi-
cient cells. Under these conditions, cells in the Rb/;E2f4/
mice that lose the wild-type Rb allele might be eliminated by
apoptosis rather than become tumorigenic. This is a reasonable
concern because there is considerable evidence supporting a
role for the E2F proteins in the regulation of many apoptosis
genes (reviewed by Trimarchi and Lees, 2002). We have not
observed any obvious difference in the apoptotic potential of
Rb/;E2f4/ versus Rb/ MEFs (our unpublished observa-
tions). However, since this does not address the consequences
of E2F4 loss in the adult pituitary and thyroid, we are attempting
to establish Rb/;E2f4/ ES cell lines that can be used to
generate chimeric mutant mice. Such mutant animals will be
invaluable because they will allow us to establish whether
Rb/;E2f4/ cells can contribute to adult tissues. Since it is
well established that the formation of tumors in Rb/ mice
depends upon the inactivation of the wild-type Rb allele, it is also
possible that the rearrangement in pocket protein complexes
in the Rb/;E2f4/ tissues somehow diminishes the selective
pressure for loss of heterozygosity. In addition, our data do not
rule out the possibility that the observed tumor-suppressive
effect of E2F4 loss is cell non-autonomous. Thus, the generation
of both conditional and chimeric mice will also be essential in
allowing us to address these two issues.
A final model suggests that E2F4 loss suppresses tumors
by simply altering the spectrum of the remaining E2F complexes.
We currently favor this hypothesis, based on our biochemical
analysis. Specifically, our data show that E2F4 loss promotes Figure 6. Model for tumor suppression resulting from simultaneous deficiency
the formation of novel E2F complexes in which p107 and p130 of E2f4 and Rb
associate with the normally pRB-specific E2Fs, E2F1 and 3 In wild-type cells, the activator E2Fs are specifically regulated by pRB while
E2F4 associates with pRB, p107, and p130. In the absence of Rb, E2F1 and(Figure 6). Previous studies have shown that inappropriate re-
E2F3 activators are released, activating inappropriate S phase target genelease of the activating E2Fs makes a major contribution to the
expression and thereby promoting uncontrolled proliferation and tumorphenotypic consequences of pRB loss (Tsai et al., 1998; Yama-
formation. The simultaneous deficiency of Rb and E2f4 in Rb/;E2f4/ mice
saki et al., 1998; Ziebold et al., 2001). We therefore propose results in the association of p107 and p130 with the activator E2Fs, conferring
that E2F4 loss suppresses tumorigenesis by increasing the free tumor-suppressive functions on p107 and p130. Loss of pRB alone also pro-
motes some binding of p107 and p130 to E2F1 and E2F3. Thus, the levels ofpools of p107 and p130 and thereby enabling them to substitute
available p107 and p130 in individual tissues may account for the tissuefor pRB in the inhibition of the activating E2Fs (Figure 6). This
specificity of Rb/ tumor formation.could also account for the observed suppression of inappropri-
ate E2F-responsive gene expression and cell cycle entry of
confluence-arrested Rb/ MEFs (Figures 5B and 5C). Additional
tumor studies will be required to distinguish between these 2000; Lee et al., 1996; Robanus-Maandag et al., 1998; Sage et
models. However, regardless of the precise mechanism by al., 2000). Specifically, pRB is a classical tumor suppressor, but
which E2F4 loss is operating, our studies do not provide any mutation of p107 and/or p130 promotes tumor formation only
support for a role of repressive E2F-pocket protein complexes when pRB is also inactivated. We believe that our observations
in tumor suppression. Instead, they strongly suggest that the can account for these differential properties. First, we propose
critical tumor suppressive role of pRB is to inhibit E2F family that tumor formation is dependent upon the inappropriate re-
members that mediate the activation of E2F-responsive genes. lease of the activating E2Fs. Since these E2Fs are specifically
Importantly, we also detected p130-E2F1 and p107-E2F3 regulated by pRB in normal cells, their release can only be
complexes in cells that had physiological levels of E2F4, but triggered by the loss of pRB and not p107 and/or p130, ex-
lacked the pRB tumor suppressor. Since the generation of Rb/ plaining why pRB is the key tumor suppressor in vivo. Second,
cells is a key step in the development of many naturally occurring our data suggest that pRB loss causes p107 and p130 to substi-
tumors, we believe that the formation of novel E2F-pocket pro- tute for pRB in the regulation of the activating E2Fs. In this
tein complexes has significant in vivo relevance. There is exten- manner, p107 and p130 become significant tumor suppres-
sive evidence from both human tumors and mutant mouse mod- sors in pRB-deficient cells. Consistent with this hypothesis,
els that the pocket proteins play non-overlapping roles in the Rb/;p107/ chimeric mice develop an additional tumor type,
retinoblastoma, compared to Rb/ chimeras (Robanus-Maan-suppression of tumors (Cobrinik et al., 1996; Dannenberg et al.,
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Confluence arrest, BrdU incorporation,dag et al., 1998), and the combined mutation of pRB, p107,
and target gene expression assaysand p130 has been shown to be highly tumorigenic (Dannenberg
MEFs were grown to confluence, and two days later, cells were labeled with
et al., 2000; Sage et al., 2000). Moreover, p107 and/or p130 10 M 5-bromo-2-deoxyuridine (BrdU; Sigma) for 8 hr. Incorporation was
mutations have been detected at a low frequency in certain quantified by indirect immunofluorescence with anti-BrdU (347580, Becton
pRB-deficient human tumors (Claudio et al., 2000a, 2000b; Helin Dickinson) antibodies and DAPI. The percentage of BrdU-positive cells was
determined by counting more than 875 cells per genotype. Whole-cell ex-et al., 1997).
tracts from day 2 confluent MEFs were prepared as previously describedIt is important to note that mutation of p107 and/or p130 is
(Moberg et al., 1996), and Western blotting was performed using anti-cyclin
not required for the formation of most pRB-deficient tumors. E (sc-481), anti-p107 (sc-318) (each from Santa Cruz Biotech), and anti-
We must therefore conclude that p107 and p130 are unable to -tubulin (T-4026, Sigma) antibodies. RT-PCR assays were carried out as
compensate for the loss of pRB in tumor-prone tissues. Inheri- described in Ren et al. (2002) using an Invitrogen RT-PCR Superscript One
Step kit.tance of germline Rb mutations results in a highly tissue-specific
tumor spectrum in both humans (retinoblastoma) and mice (pitu-
Acknowledgmentsitary and thyroid tumors). Since pRB is believed to play a key
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